TARS in the 13F filings
Tarsus Pharmaceuticals Inc · CUSIP 87650L103
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 2 Sep 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 3 listed it in both
- Shares listed
- 8,497,588
- combined, among listed positions
- Reported value
- $535m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 16 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,750,041.
Managers listing TARS in Q2 2026
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 1,427,124 shares now+862,545
- Janus Henderson Group Ltdexisting position · 2,808,796 shares now+567,833
- MFS Investment Managementnew position · 427,008 shares now+427,008
- Schonfeld Strategic Advisors LLCnew position · 99,845 shares now+99,845
- Citadel Advisors LLCexisting position · 241,737 shares now+77,740
Reductions
- D. E. Shaw & Co.existing position · 710,559 shares now-80,587
- Renaissance Technologies LLCexisting position · 9,300 shares now-64,100
- Fidelity (FMR LLC)existing position · 672,949 shares now-60,385
- PDT Partners LLCexisting position · 32,292 shares now-30,734
- Artisan Partners LPexisting position · 284,899 shares now-22,408
New positions and exits
New (5)
Exited (3)
- Point72 Asset Management LPwas $16m
- Man Group PLCwas $1.6m
- Caxton Associates LLPwas $1.1m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2021 | 1 | $397k | n.a. | n.a. |
| Q3 2023 | 2 | $14m | n.a. | n.a. |
| Q4 2023 | 2 | $13m | 0 | 2 |
| Q1 2024 | 2 | $31m | 1 | 1 |
| Q2 2024 | 2 | $35m | 2 | 0 |
| Q3 2024 | 5 | $62m | 5 | 0 |
| Q4 2024 | 4 | $46m | 2 | 2 |
| Q1 2025 | 1 | $31m | 0 | 1 |
| Q2 2025 | 3 | $98m | 2 | 1 |
| Q3 2025 | 3 | $122m | 1 | 1 |
| Q4 2025 | 4 | $202m | 18 | 10 |
| Q1 2026 | 4 | $184m | 14 | 14 |
| Q2 2026 | 4 | $201m | 16 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TARS and GILD →TARS and AMGN →TARS and ARGX →Choose a stock to compare with TARS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TARS, latest filings →Back to the 13F Explorer →